DNTH — Dianthus Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.17bn
- $3.28bn
- $2.04m
Magenta Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Ruth's Hospitality, Mirion Technologies, Qualcomm
U.S. STOCKS ON THE MOVE-CVS Health, Match Group, Western Union
Magenta Therapeutics rises on merger agreement with Dianthus Therapeutics
Brief: Magenta Therapeutics And Dianthus Therapeutics Announce Merger Agreement
Brief: Magenta Therapeutics - On March 31, Co Entered Into Sublease Termination, Release Agreement With Novartis Institutes For Biomedical Research
Brief: Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan
Magenta Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Magenta Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: Magenta Therapeutics Inc Says As Of Dec 31, 2022, Co's Cash, Cash Equivalents, Marketable Securities Were About $112 Mln
Magenta Therapeutics surges on plans to pursue strategic options
Brief: Magenta Therapeutics Inc Received Notice From Nasdaq That Co Is Not Been In Compliance With Minimum Bid Price Requirement
Brief: Magenta Therapeutics To Explore Strategic Alternatives
U.S. STOCKS ON THE MOVE-Foot Locker, Nemaura, Chipotle
U.S. STOCKS ON THE MOVE-TD Synnex, Nucor, Pfizer
U.S. STOCKS ON THE MOVE-Xerox, AC Immune, OpGen
U.S. STOCKS ON THE MOVE-Tesla, Aridis Pharmaceuticals, BuzzFeed
Magenta tanks on pausing blood cancer therapy trial after death of participant
Brief: Magenta Therapeutics Voluntarily Pauses Blood Cancer Therapy Trial To Investigate Drug Safety